Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $75.5 million, with product revenue net of $59.9 million, an increase from $51.9 million in Q3 2025 and $54.4 million in Q4 2024 [5][21] - Royalty revenue was $15.6 million in Q4 2025, compared to $2.6 million in Q3 2025 and $4.7 million in Q4 2024 [6][30] - Net income based on GAAP for Q4 2025 was $13.4 million, or $0.20 per basic share, compared to $8.8 million in Q3 2025 [27] Business Line Data and Key Metrics Changes - NERLYNX sales included U.S. net sales of $55.2 million in Q4 2025, up from $51.8 million in Q3 2025 [30] - Total prescriptions for NERLYNX increased by approximately 1.4% quarter-over-quarter, while new prescriptions decreased by about 11.4% [6][24] - NERLYNX ex-factory bottle sales were 3,298 in Q4 2025, representing a 12% increase quarter-over-quarter [22] Market Data and Key Metrics Changes - The distribution model showed that 63% of business was purchased through the specialty pharmacy (SP) channel, while 37% was through the specialty distributor (SD) channel [19] - Demand in the SD channel grew by about 17% quarter-over-quarter and 46% year-over-year [24] Company Strategy and Development Direction - The company is focused on increasing awareness of NERLYNX's dual indication in HER2-positive breast cancer and enhancing clinical education [16] - Puma is evaluating several drugs for potential in-licensing or acquisition to diversify its portfolio [15] Management's Comments on Operating Environment and Future Outlook - Management expressed commitment to maintaining positive net income and financial discipline, guiding for continued profitability in 2026 [38] - The company anticipates net NERLYNX product revenue for fiscal year 2026 to be in the range of $194 million to $198 million [32] Other Important Information - The company reported cash earned of approximately $3.1 million in Q4 2025, with total outstanding principal debt decreasing to approximately $22 million [36] - The company plans to initiate a second trial of alisertib in small cell lung cancer [14] Q&A Session Summary Question: Can you speak to the dynamics around the inventory build this fourth quarter? - Management noted that inventory builds are typical at the end of the year, driven by expectations of price increases [42] - It was mentioned that inventory usually burns off in the first quarter following the fourth quarter build [43]